Nothing Special   »   [go: up one dir, main page]

Boros et al., 2020 - Google Patents

Classification of metal-based drugs according to their mechanisms of action

Boros et al., 2020

View HTML @Full View
Document ID
4667535459795361808
Author
Boros E
Dyson P
Gasser G
Publication year
Publication venue
Chem

External Links

Snippet

Metal-based drugs and imaging agents are extensively used in the clinic for the treatment and diagnosis of cancers and a wide range of other diseases. The current clinical arsenal of compounds operate via a limited number of mechanisms, whereas new putative compounds …
Continue reading at www.cell.com (HTML) (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
    • A61K51/0474—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody or an immunoglobulin, or a fragment thereof, e.g. a camelised human single domain antibody, or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody or an immunoglobulin, or a fragment thereof, e.g. a camelised human single domain antibody, or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation; Therapies using these preparations
    • A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy

Similar Documents

Publication Publication Date Title
Boros et al. Classification of metal-based drugs according to their mechanisms of action
Chen et al. Porphyrin‐based metal–organic frameworks for biomedical applications
Preihs et al. Recent developments in texaphyrin chemistry and drug discovery
Storr et al. Design of targeting ligands in medicinal inorganic chemistry
Schatzschneider PhotoCORMs: Light-triggered release of carbon monoxide from the coordination sphere of transition metal complexes for biological applications
Ciesienski et al. Keys for unlocking photolabile metal‐containing cages
Stemmler et al. The preparation, characterization, and magnetism of copper 15-metallacrown-5 lanthanide complexes
Lima et al. Monopicolinate cyclen and cyclam derivatives for stable copper (II) complexation
Barry et al. Exploration of the medical periodic table: towards new targets
Pietrangeli et al. Carboranyl-porphyrazines and derivatives for boron neutron capture therapy: From synthesis to in vitro tests
Karges et al. Polymeric encapsulation of a Ru (II)-based photosensitizer for folate-targeted photodynamic therapy of drug resistant cancers
Chiang et al. Multifunctional ligands in medicinal inorganic chemistry-current trends and future directions
Pettenuzzo et al. Vitamin B12–metal conjugates for targeted chemotherapy and diagnosis: Current status and future prospects
Imberti et al. 150 years of the periodic table: New medicines and diagnostic agents
Yu et al. Adding a second quinol to a redox-responsive MRI contrast agent improves its relaxivity response to H2O2
Brewster et al. Porphyrinoid f-element complexes
Lengacher et al. Medicinal inorganic chemistry–challenges, opportunities and guidelines to develop the next generation of radioactive, photoactivated and active site inhibiting metal-based medicines
Redrado et al. Theranostics through the synergistic cooperation of heterometallic complexes
Kilian et al. The fast method of Cu-porphyrin complex synthesis for potential use in positron emission tomography imaging
Souris et al. X-ray activated nanoplatforms for deep tissue photodynamic therapy
Li et al. Iridium (III)-Based Infrared Two-Photon Photosensitizers: Systematic Regulation of Their Photodynamic Therapy Efficacy
Grieve et al. The synthesis of a bis (Thiosemicarbazone) macrocyclic ligand and the Mn (II), Co (II), Zn (II) and 68Ga (III) complexes
Imberti et al. Radiometal-Labeled Photoactivatable Pt (IV) Anticancer Complex for Theranostic Phototherapy
Harriswangler et al. Versatile macrocyclic platform for the complexation of [natY/90Y] yttrium and lanthanide ions
Tisato et al. Contribution of electrospray mass spectrometry for the characterization, design, and development of nitrido technetium and rhenium heterocomplexes as potential radiopharmaceuticals